Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2006, Pages 85-90

  Chen, J J ^a   Lin, C Y ^a   Sheu, M J ^a   Kuo, H T ^a   Sun, C S ^a   Tang, L Y ^a   Wang, S L ^a   Tsai, S L ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOANALYSIS; BLOOD ANALYSIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; MONOTHERAPY; PRIORITY JOURNAL; SEROLOGY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN M; LAMIVUDINE; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 33644894813     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02718.x     Document Type: Article

References (37)

1. Lai CL Chien RH Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 1998 339 61 8
2. Jarvis B Faulds D Lamivudine. A review of its therapeutic potential in chronic hepatitis B Drugs 1999 58 101 41
3. Dienstag JL Schiff ER Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 1999 341 1256 63
4. Liaw YF Leung NWY Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 2000 119 172 80
5. Jonas MM Kelley DA Mizerski J et al. Clinical trial of lamivudine in children with chronic hepatitis B N Engl J Med 2002 346 1706 13
6. Doong SL Tsai CH Schinazi RF et al. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-Dideoxy-3′-thiacytidine and related analogues Proc Natl Acad Sci USA 1991 88 8495 9
7. Dienstag JL Perillo RP Schiff ER et al. A Preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 1995 333 1657 61
8. Mckenzie R. Fried MW Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B N Engl J Med 1995 333 1099 105
9. Liaw YF Sung JJY Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 2004 351 1521 31
10. Dienstag JL Goldin RD Heathcote EJ et al. Histological outcome during long-term lamivudine therapy Gastroenterology 2003 124 105 17
11. Dusheiko G Bertoletti A Resistance to lamivudine therapy: is there more than meets the eye Gut 2005 54 9 10
12. Zavaglia C Mondazzi L Maggi G et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B Liver 1997 17 83 7
13. Mels GC Bellati G Leandro G et al. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations Liver 1994 14 175 81
14. Smith HM Lau JY Davies SE et al. Significance of serum IgM anti-HBc in chronic hepatitis B virus infection J Med Virol 1992 36 16 20
15. Gerlich WH Uy A Lambrecht F Thomssen R Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections J Clin Microbiol 1986 24 288 93
16. Sjogren M Hoofnagle JH Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis Gastroenterology 1985 89 252 8
17. Surrenti C Ambu S Patussi V et al. Diagnostic significance of anti-HBc IgM (RIA) in healthy HBsAg carriers and in chronic hepatitis B J Med Virol 1986 18 229 34
18. Marinos G Smith HM Naoumov NV Williams R Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection Hepatology 1994 19 303 11
19. Scully LJ Brown D Lloyd C Shein R Thomas HC Immunological studies before and during interferon therapy in chronic HBV infection: identification of factors predicting response Hepatology 1990 12 1111 7
20. Chen G Karayiannis P McGarvey MJ et al. Subclasses of antibodies to hepatitis B core antigen in chronic HBV infection: changes during treatment with alpha interferons and predictors of response Gut 1989 30 1123 8
21. Perrillo R Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease Gastroenterology 2001 20 1009 22
22. Tsai SL Chen PJ Lai MY et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens J Clin Invest 1992 89 7 96
23. Wong DKH Cheung AM ÒRourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis Ann Intern Med 1993 119 319 23
24. Stark GR Kerr IM Williams BR et al. How cells respond to interferons Annu Rev Biochem 1998 67 227 64
25. Levy DE Marié I Prakash A Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity Curr Opin Immunol 2003 15 52 58
26. Müller U Steinhoff U Reis LFL et al. Functional role of type I and type II interferons in antiviral defense Science 1994 264 1918 24
27. Gordien E Rosmorduc O Peltekian C et al. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein J Virol 2001 75 2684 91
28. Boni C Bertoletti A Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B J Clin Invest 1998 02 968 75
29. Hultgren C Weiland O Milich DR Sallberg M Cell-mediated immune responses and loss of hepatitis Be antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection Clin Infet Dis 1999 29 1575 7
30. Boni C Penna A Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy Hepatology 2001 33 963 71
31. Lin CL Tsai SL Lee TH Chien RN Liao SK Liaw YF High frequency of functional anti-YMDD and - mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B Gut 2005 54 152 61
32. Liaw YF Tsai SL Chien RN et al. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B Hepatology 2000 32 604 9
33. Tsai SL Sheen IS Chien RN et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications J Biomed Sci 2003 10 120 35
34. Tsai SL Lee TH Chien RN et al. A method to increase tetramer-staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment J Immunol Methods 2004 285 71 87
35. Chang TT Lai CL Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 2004 19 1276 82
36. Liaw YF Results of lamivudine trials in Asia J Hepatol 2003 39 S111 5
37. Chien RN Yeh CT Tsai SL et al. The determinants for sustained HBeAg response to lamivudine therapy Hepatology 2003 8 1267 73